Convergence of Cell Pharmacology and Drug Delivery

Ayesha Aijaz, Natalie Vaninov, Ashley Allen, Rita N. Barcia, Biju Parekkadan

Research output: Contribution to journalArticle

Abstract

Cellular therapy is enabling new approaches to tackle significant unmet needs in areas such as regenerative medicine and immunotherapy. The pharmacology of cell therapeutics becomes of critical importance to assure that these new drugs work reproducibly and effectively. Cell pharmacology can benefit from adapting principles of classical molecular drug pharmacokinetics (PK) and pharmacodynamics (PD) to quantitatively understand rate-limiting constraints of cell fate after administration. Future innovations focused on improvements in drug delivery using a PK/PD perspective can aid in designing a cell therapeutic product to overcome any pharmacological barriers for a given disease application. Herein, we present a perspective on the development of an ex vivo mesenchymal stromal therapeutic using a PK/PD framework and also present examples of general cell engineering techniques that implicitly influence the PK/PD curve by genetically modifying cells to regulate their in vivo duration, biodistribution, and activity. Stem Cells Translational Medicine 2019;8:874&879.

Original languageEnglish (US)
Pages (from-to)874-879
Number of pages6
JournalStem Cells Translational Medicine
Volume8
Issue number9
DOIs
StatePublished - Jan 1 2019

Fingerprint

Pharmacology
Pharmacokinetics
Pharmaceutical Preparations
Cell Engineering
Regenerative Medicine
Translational Medical Research
Therapeutics
Immunotherapy
Stem Cells

All Science Journal Classification (ASJC) codes

  • Developmental Biology
  • Cell Biology

Cite this

Aijaz, Ayesha ; Vaninov, Natalie ; Allen, Ashley ; Barcia, Rita N. ; Parekkadan, Biju. / Convergence of Cell Pharmacology and Drug Delivery. In: Stem Cells Translational Medicine. 2019 ; Vol. 8, No. 9. pp. 874-879.
@article{e9ccaf64ae2a430e8ec2a40e5c71f427,
title = "Convergence of Cell Pharmacology and Drug Delivery",
abstract = "Cellular therapy is enabling new approaches to tackle significant unmet needs in areas such as regenerative medicine and immunotherapy. The pharmacology of cell therapeutics becomes of critical importance to assure that these new drugs work reproducibly and effectively. Cell pharmacology can benefit from adapting principles of classical molecular drug pharmacokinetics (PK) and pharmacodynamics (PD) to quantitatively understand rate-limiting constraints of cell fate after administration. Future innovations focused on improvements in drug delivery using a PK/PD perspective can aid in designing a cell therapeutic product to overcome any pharmacological barriers for a given disease application. Herein, we present a perspective on the development of an ex vivo mesenchymal stromal therapeutic using a PK/PD framework and also present examples of general cell engineering techniques that implicitly influence the PK/PD curve by genetically modifying cells to regulate their in vivo duration, biodistribution, and activity. Stem Cells Translational Medicine 2019;8:874&879.",
author = "Ayesha Aijaz and Natalie Vaninov and Ashley Allen and Barcia, {Rita N.} and Biju Parekkadan",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/sctm.19-0019",
language = "English (US)",
volume = "8",
pages = "874--879",
journal = "Stem cells translational medicine",
issn = "2157-6564",
publisher = "AlphaMed Press",
number = "9",

}

Convergence of Cell Pharmacology and Drug Delivery. / Aijaz, Ayesha; Vaninov, Natalie; Allen, Ashley; Barcia, Rita N.; Parekkadan, Biju.

In: Stem Cells Translational Medicine, Vol. 8, No. 9, 01.01.2019, p. 874-879.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Convergence of Cell Pharmacology and Drug Delivery

AU - Aijaz, Ayesha

AU - Vaninov, Natalie

AU - Allen, Ashley

AU - Barcia, Rita N.

AU - Parekkadan, Biju

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Cellular therapy is enabling new approaches to tackle significant unmet needs in areas such as regenerative medicine and immunotherapy. The pharmacology of cell therapeutics becomes of critical importance to assure that these new drugs work reproducibly and effectively. Cell pharmacology can benefit from adapting principles of classical molecular drug pharmacokinetics (PK) and pharmacodynamics (PD) to quantitatively understand rate-limiting constraints of cell fate after administration. Future innovations focused on improvements in drug delivery using a PK/PD perspective can aid in designing a cell therapeutic product to overcome any pharmacological barriers for a given disease application. Herein, we present a perspective on the development of an ex vivo mesenchymal stromal therapeutic using a PK/PD framework and also present examples of general cell engineering techniques that implicitly influence the PK/PD curve by genetically modifying cells to regulate their in vivo duration, biodistribution, and activity. Stem Cells Translational Medicine 2019;8:874&879.

AB - Cellular therapy is enabling new approaches to tackle significant unmet needs in areas such as regenerative medicine and immunotherapy. The pharmacology of cell therapeutics becomes of critical importance to assure that these new drugs work reproducibly and effectively. Cell pharmacology can benefit from adapting principles of classical molecular drug pharmacokinetics (PK) and pharmacodynamics (PD) to quantitatively understand rate-limiting constraints of cell fate after administration. Future innovations focused on improvements in drug delivery using a PK/PD perspective can aid in designing a cell therapeutic product to overcome any pharmacological barriers for a given disease application. Herein, we present a perspective on the development of an ex vivo mesenchymal stromal therapeutic using a PK/PD framework and also present examples of general cell engineering techniques that implicitly influence the PK/PD curve by genetically modifying cells to regulate their in vivo duration, biodistribution, and activity. Stem Cells Translational Medicine 2019;8:874&879.

UR - http://www.scopus.com/inward/record.url?scp=85065964065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065964065&partnerID=8YFLogxK

U2 - 10.1002/sctm.19-0019

DO - 10.1002/sctm.19-0019

M3 - Article

C2 - 31091020

AN - SCOPUS:85065964065

VL - 8

SP - 874

EP - 879

JO - Stem cells translational medicine

JF - Stem cells translational medicine

SN - 2157-6564

IS - 9

ER -